Cosmetics
AstraZeneca indicators as much as US$18.5 billion weight problems drug cope with China’s CSPC
02
Feb
Feb
THE WHAT? AstraZeneca has agreed a serious obesity-focused licensing cope with China’s CSPC Pharmaceutical Group, value as much as US$18.5 billion, because it accelerates its push into the fast-growing weight-loss market. THE DETAILS Below the settlement, AstraZeneca pays US$1.2 billion upfront for rights to eight weight problems drug candidates, together with 4 injectable therapies. The […]
